Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

£280m plus VAT: the average cost of a fully-equipped new UK district hospital

This article was originally published in Clinica

Executive Summary

A new 418-bed hospital, fully equipped with operating theatres, A&E, pathology and radiography, among other support services, costs approximately £280m ($425m), excluding value-added tax (VAT), in England. Health minister Ben Bradshaw revealed the cost to parliament on April 30 and said that the "indicative cost of building a medium-sized general acute hospital" reflects the current business case approval information. The amount comprises capital construction and equipment costs and professional fees. Hospital-building costs have come under scrutiny in the light of government plans to establish a network of smaller community hospitals, backed by large general practices – so-called super-surgeries – replacing some district hospitals.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT041843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel